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Introduction
Biologics are often used in therapy of DMARDs resis-
tant JIA. The most complicated problem is choosing
specific biological agent in particular case. AntiTNF
inhibitors are well studied, but the application of Abata-
cept in real clinical practice hasn’t been investigated
enough.
Objectives
Retrospective evaluation of the ABA therapy results in
process of treating children with JIA.
Methods
The analysis includes data of 60 patients with JIA who
were getting ABA in 2010 - 2013. The average age of
patients is 12,5 years (from 6 to 18 years). 21 (35%)
patients suffered from active uveitis (2 patients had one
eye affection, 19 had affection of both eyes). 10 (16%)
patients were diagnosed as sJIA without current systemic
features. Patients received ABA intravenously at a dosage
of 10 mg/kg with 2 weeks interval initially (3 infusion)
and following every month administration. Efficacy was
evaluated in accordance with ACRpedi criteria. Ocular
manifestations were evaluated by ophthalmologists.
Results
43 (72%) patients continue ABA therapy, in 17 cases
ABA was cancelled (in 3 cases due to infusion/allergy
reactions, in 9 cases due to the inefficacy of application,
in 5 cases due to some other reasons). 30% patient (18
cases) failed to comply with the infusion schedule due
to organization problems.
The efficiency of ABA according to the ACRpedi cri-
teria is demonstrated in Table 1.
The efficacy of ABA was increased significantly after 12
months of therapy. The regularity of infusions influences
the higher effect, thus 70-90% improvement after 12
months were achieved predominantly in patients who had
no deviations in infusion regimen (30 vs 4). ABA used as
first-line biological agent more often shows 70-90%
improvement after 12 months (27 vs 7 antiTNF-failers).
Uveitis remission was identified in 53% of cases after
6 months, in 73% of cases - after 12 months, in 69% of
cases - after 18 months, in 67% of cases - after 24 four
months. 7 patients had adverse events (3 patients has
post-infusion reactions, 2 patients (the both with early
pauciarthicular onset) had uveitis de-novo, 1 patient had
body weight gain, 1 patient had verruca vulgaris) but no
serious events were observed.
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3 (n = 55) 6 (n = 54) 9 (n = 51) 12 (n = 43) 18 (n = 33) 24 (n = 24) 30 (n = 9)
30% 51% 13% 2% 2% 0 4% 0
50% 49% 63% 24% 12% 15% 8% 0
70% 0 24% 55% 44% 24% 17% 11%
90% 0 0 6% 35% 55% 63% 67%
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Conclusion
Long-term application of ABA is supposed to be highly
efficient for treatment of patients with JIA, including
patients with uveitis. The increase of positive effect ABA
has continued to increase after 24 month period of ther-
apy. The efficiency of ABA depends on the correct infu-
sion regimen and it is higher in biologics-naïve patients.





1Paediatric, Federal State Budgetary Institution “Research Institute of
Rheumatology” under Russian Academy of Medical Science, Russian
Federation. 2Paediatric, Central Children Hospital FMBA, Moscow, Russian
Federation.
Published: 5 December 2013
doi:10.1186/1546-0096-11-S2-P73
Cite this article as: Arsenyeva et al.: PReS-FINAL-2061: Abatacept in
therapy of juvenile idiopathic arthritis in real clinical practice. Pediatric
Rheumatology 2013 11(Suppl 2):P73.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Arsenyeva et al. Pediatric Rheumatology 2013, 11(Suppl 2):P73
http://www.ped-rheum.com/content/11/S2/P73
Page 2 of 2
